Semaglutide 2.4 mg produces weight-independent liver benefits among individuals with metabolic dysfunction-associated steatohepatitis.
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY ...
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis ...
The ABC can reveal that in July last year, Queensland Health department became aware of "inconsistencies" in records of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback